orantinib has been researched along with su9518 in 1 studies
| Studies (orantinib) | Trials (orantinib) | Recent Studies (post-2010) (orantinib) | Studies (su9518) | Trials (su9518) | Recent Studies (post-2010) (su9518) |
|---|---|---|---|---|---|
| 110 | 19 | 36 | 5 | 0 | 2 |
| Protein | Taxonomy | orantinib (IC50) | su9518 (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 1.28 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 1.51 | |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | 1.898 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 1.128 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liang, C; McMahon, G; Rice, A; Schreck, R; Shawver, LK; Sun, L; Tang, C; Tang, F; Tran, N; Waltz, K | 1 |
1 other study(ies) available for orantinib and su9518
| Article | Year |
|---|---|
Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases.
Topics: Drug Design; Drug Evaluation, Preclinical; Endothelial Growth Factors; Enzyme Inhibitors; Fibroblast Growth Factors; Humans; Indoles; Lymphokines; Magnetic Resonance Spectroscopy; Mass Spectrometry; Molecular Structure; Platelet-Derived Growth Factor; Receptor Protein-Tyrosine Kinases; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 1999 |